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Ⅰ．Introduction
 Kawasaki disease （KD; MIM 611775）, also 
known as mucocutaneous lymph node syndrome, was 
first described in 1967 by Dr. Tomisaku Kawasaki, a 
graduate of Chiba University［1］. KD is a systemic 
vasculitis that predominantly affects infants and 
children under 5 years of age is characterized by high 
fever, polymorphous skin rash, bilateral conjunctivitis, 
palmar/plantar erythema followed by membranous 
desquamation, redness of the oral mucosa and lips, and 
non-suppurated cervical lymphadenopathy. KD was 
initially thought to be a benign disorder due to its self-
limiting nature in many cases. However, an investigation 
into rare cases of sudden death in KD revealed that most 
died due to rupture or occlusion of giant coronary artery 
aneurysms; in fact, it was found that 20-25% of KD 
patients develop coronary artery aneurysm or dilation if 
they do not receive adequate treatment in the acute phase
［2］. It is these cardiac sequelae that have made KD a 
leading cause of acquired heart disease in developed 
countries. Previous nationwide outbreaks experienced 
in 1979, 1982, and 1986 in Japan and seasonal changes 
in the incidence rate indicate the involvement of an 
infectious agent in the etiology of KD. However, despite 
intensive research, the etiological agent responsible for 
triggering the disease has not been identified. In the 
meantime, epidemiological studies have highlighted 
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SUMMARY
Kawasaki disease （KD） is a systemic vasculitis of unknown etiology that mainly affects 
infants and children. To unravel the genetic background of KD, we have been searching for relevant 
susceptibility genes. As the first step, we performed a genome-wide linkage study and identified 10 
candidate chromosomal regions. In a subsequent case-control association study of single nucleotide 
polymorphisms （SNPs） mapped within the candidate regions, we identified functional SNPs of ITPKC 
and CASP3 that were significantly associated with KD. In a genome-wide association study of KD, we 
then identified the SNPs conferring KD susceptibility in the FAM167A-BLK, CD40, and HLA class II 
gene regions. We also confirmed the previously reported association of a functional SNP of FCGR2A. 
These findings have provided further insight into the pathogenesis of KD. In particular, by identifying 
a synergistic association of the susceptibility alleles of ITPKC and CASP3 which confer risks for 
intravenous immunoglobulin resistance and coronary artery lesion formation, our group highlighted 
the importance of Ca2+/NFAT pathway activation in KD pathogenesis. On this theoretical basis, we 
support the administration of cyclosporine, a drug that targets this pathway, in cases of refractory KD.
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a marked difference in disease prevalence among 
ethnicities. The most recent worldwide annual incidence 
rates per 100,000 children aged 0-4 years was highest 
in Japan （264.8）［3］, followed in order by Korea 
（134.4） and Taiwan （66.2）［4,5］. Familial aggregation 
of KD is also known to occur［6-8］. Thus KD has been 
recognized as a multifactorial disease, the etiology of 
which involves both environmental and genetic factors. 
To unravel the genetic background of KD, we have been 
supporting genome-wide searches for KD susceptibility 
genes.
Ⅱ．Genome-wide linkage study
 Because candidate gene study was thought to be 
less efficient for complex disorders, especially when 
information about their pathophysiology is limited, 
we adopted a genome-wide approach in which we 
made no assumptions about the relevance of candidate 
genes and considered all genes in the human genome 
as candidates. As the first step in our research, we 
conducted a genome-wide linkage study in efforts to 
map susceptibility genes to chromosomes. Using an 
affected sib-pair method, we assessed allele sharing 
of genetic markers among sibling pairs in whom both 
were affected with KD, and searched for markers with 
alleles shared between them at an above-expected rate. 
In this analysis, excess allele sharing indicates linkage 
between the marker and the disease gene. A total of 399 
microsatellite markers selected at an average interval 
of 9.9 cM from 22 autosomes and the X chromosome 
were genotyped for 78 affected sib-pairs with KD 
and their family members. Ten chromosomal regions 
（4q35, 5q34, 6q27, 7p15, 8q24, 12q24, 18q23, 19q13, 
Xp22, and Xq27; Figure 1） showing a nominal trend of 
linkage （MLS＞1.0） were identified［9］. This was the 
first successful genome-wide study for KD and led to 
the identification of 2 susceptibility genes.
Ⅲ． Identification of susceptibility genes from 
candidate regions with positive linkage 
signals
 We continued narrowing down the candidate regions 
identified in the linkage study. Using information 
from the SNP map constructed in Japan as part of the 
Japanese Millennium Genome Project, we selected SNPs 
near each linkage peak and compared allele frequencies 
between KD cases and controls. In this linkage 
disequilibrium mapping, we found multiple SNPs in the 
19q13.2 region that showed replicable association with 
KD［10］. Through studies of gene and SNP function, 
we concluded that the inositol 1,4,5-trisphosphate 
3-kinase C gene （ITPKC） was the susceptibility gene of 
the locus and that the rs28493229 SNP was responsible 
for this susceptibility. We found that the amount of 
ITPKC transcripts from the associated allele （C） of 
the SNP was reduced in peripheral blood mononuclear 
cells （PBMCs） compared with that from the opposite 
allele （G）, and that this difference was due to change 
in the splicing efficiency of intron 1 of the gene. The 
rs28493229 SNP is located at the 9th nucleotide position 
of ITPKC intron 1, and we found that the transcripts 
from the C allele may persist unspliced until being 
degraded by the nonsense-mediated decay mechanism. 
ITPKC is a kinase of inositol 1,4,5-trisphosphate （IP3）, 
Fig. 1　Results of sibling pair linkage analysis.
　Ten chromosomal regions have positive linkage signals （MLS＞1.0）. Chromosome numbers 1-22 and X 
are shown on the X-axis.
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expression is thought to allow sustained activation of 
immune cells and progression of KD inflammation. 
Association of both ITPKC and CASP3 SNPs with KD 
susceptibility has gained credibility after validation in 
multiple ethnicities［12-14］.
Ⅳ．Genome-wide association study
 Development of high throughput genotyping 
platforms for SNPs has made genome-wide scans of 
susceptibility genes of complex diseases a reality. In 
particular, establishment of the genome-wide association 
study （GWAS） method has dramatically promoted 
these studies. Today, 9 GWAS papers for KD have been 
published and a number of genomic regions have been 
proposed in one or more papers as susceptibility loci for 
KD. However, many of these regions failed to satisfy 
the formal significance thresholds used in genome-
wide studies and therefore required further follow up 
or validation. Along with ITPKC and CASP3 genes, 
associations of SNPs in the FCGR2A, BLK, and CD40 
gene regions identified in GWAS to date have been 
validated in multiple ethnic groups and are generally 
considered to be credible susceptibility genes or loci 
for KD. Through our work, we have contributed to the 
identification of association signals in BLK and CD40 
gene regions. In our GWAS, significant and reproducible 
association of the SNPs in the HLA class II gene region 
was also identified.
FCGR2A
 In 2011, an international consortium for the genetic 
study of KD organized by Dutch, British, Australian, 
and American researchers reported results of a GWAS 
conducted among European KD patients［13］. In this 
study, SNPs near the Fc gamma receptor （FCGR） 
gene cluster located on the chromosome 1q23 region 
were significantly associated with KD. Association of 
a functional SNP of Fc fragment of IgG, low affinity 
IIa, receptor （FCGR2A） gene （rs1801274 A/G） 
was the most significant and the A allele confers KD 
susceptibility. FCGR2A expressed on neutrophils and 
macrophages transduces the activation signal when 
which is generated by hydrolysis of phosphatidylinositol 
4,5-bisphosphate in response to stimulation of various 
cell surface receptors such as T-cell, B-cell, Fc gamma, 
and G-protein-coupled receptors. IP3 acts as a second 
messenger molecule in downstream signal transduction. 
ITPKC might therefore downregulate the Ca2+/NFAT 
pathway by phosphorylating IP3 into IP4, which does 
not bind to the IP3 receptor, consequently preventing 
signal transduction （Figure 2）.
 By applying positional candidate gene study to 
the 4q35 region, we identified SNPs associated with 
KD around caspase-3 （CASP3）. Sequences around 
rs113420705, one of the associated SNPs and located 
in exon 1 of CASP3, has enhancer activity related to 
nuclear factor of activated T-cells （NFAT）; owing to 
alteration of the activity, the risk allele （A） expresses 
smaller amount of CASP3 mRNA in PBMCs than the 
opposite allele （G）［11］. As CASP3 is known to play a 
pivotal role in immune cell apoptosis, reduced CASP3 
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Fig. 2　 Possible roles of KD susceptibility genes in the 
Ca2+/NFAT pathway. 
　B C R :  B - c e l l  r e c e p t o r ;  C A S P3 :  c a s p a s e -3 ; 
CsA: cyclosporine A; DAG: diacylglycerol; ER: 
endoplasmic reticulum; FCGRs: Fc gamma receptors; 
GPCRs: G-protein-coupled receptors; IP3: inositol 
1,4,5-trisphosphate; IP3R: inositol 1,4,5-trisphosphate 
receptor; IP4: inositol 1,3,4,5-tetrakisphosphate; ITPKC: 
inositol 1,4,5-trisphosphate 3-kinase C; NFAT: nuclear 
factor of activated T-cells; PIP2: phosphatidylinositol 
4 ,5-bisphosphate; PKC: protein kinase C; PLC: 
phospholipase C; TCR: T-cell receptor.
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ligated with immune complexes and clustered on the 
cell surface. The A-to-G substitution results in a change 
of translation of the 131st amino acid from histidine 
to arginine; the histidine type corresponding to the 
associated allele （A） has higher binding affinity to the 
IgG2 subclass. We validated the association with this 
SNP in our GWAS samples and also found that the A 
allele was overrepresented in Japanese KD patients［15］.
BLK
 In two independent GWAS for KD, conducted by 
our group［15］and a Taiwanese group［16］, significant 
associations of SNPs located in chromosome 8p23-p22 
region were observed. The association in this locus was 
highest at the intergenic region between the family with 
sequence similarity 167, member A （FAM167A） and B 
lymphoid kinase （BLK） genes. SNPs in this area have 
been associated with multiple autoimmune diseases. 
BLK is expressed mainly in B cells and is involved in 
B-cell receptor signaling. Because B calls play a central 
role in autoimmunity, BLK rather than FAM167A, which 
has not been functionally characterized, is generally 
taken to be a susceptibility gene in autoimmune diseases.
CD40
 CD40, also known as TNF receptor superfamily 
member 5, is located on chromosome 20q12-q13.2. 
CD40, which is expressed on the cell surface of antigen 
presenting cells and vascular endothelial cells among 
others, is stimulated when ligated with CD40L, its 
counterpart expressed on activated CD4 T cells and 
platelets, and it transduces activation or differentiation 
signals into the cells. Significant association of the SNPs 
around CD40 with KD susceptibility was reported in 
the two GWA studies mentioned above［15,16］. The 
associated SNPs were in linkage disequilibrium with 
known functional SNP-altering efficiency of CD40 
protein translation （rs1883832 C/T）, and the C allele, 
which corresponds to higher CD40 protein expression, is 
linked with alleles of the SNPs conferring susceptibility 
to KD in this area. As is the case with BLK, CD40 is 
a known common susceptibility gene for autoimmune 
diseases.
HLA class II
 SNPs in the HLA class II region also showed a 
significant association in our GWAS. The association 
peaked at the intergenic region between HLA-DQB2 
and HLA-DOB［15］. Although we confirmed a positive 
association of the SNPs in this region in an independent 
case-control set, association signals observed for the 
SNPs in this region were not significant in GWAS 
conducted among other ethnicities. It is therefore 
likely that there is a genetic variant that determines 
susceptibility to KD in the HLA class II region, at 
least in the Japanese population. However, further 
study is needed to judge whether the variation is 
Japanese-specific or not. Although extended linkage 
disequilibrium and numerous genes with high sequence 
homology as well as densely distributed variations in 
this area make the determination of true susceptibility 
genes and variants challenging, the finding of this 
association in the HLA class II region might serve as a 
clue to elucidate the controversial contribution of HLA 
to KD pathogenesis.
Ⅴ． Common genetic background between KD 
and other inflammatory disorders
 Pathologically, KD has been defined as a vasculitis 
that mainly affects small and medium-sized arteries. 
However, definitive categorization of KD into disease 
groups has not been made from the viewpoint of 
underlying pathophysiology. As mentioned above, 
genome-wide studies have revealed previously unknown 
commonalities in genetic factors between KD and other 
Fig. 3 Overlapping of genetic factors for KD and those 
for other immune or inflammatory diseases 
unraveled by genome-wide studies.
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inflammatory diseases （Figure 3）. However, variants 
of ITPKC and CASP3 were not previously associated 
in any GWAS for other diseases. This indicates that the 
genetic basis of KD is structured by multiple factors: 
those shared with other diseases as well as those highly 
specific for KD. Accumulation of knowledge on 
these factors will undoubtedly help us understand the 
pathophysiology of the disease and might highlight the 
applicability of existing therapies for other diseases to 
KD.
Ⅵ． Progress toward clinical application of 
research findings
 A combination of oral aspirin and a high dose 
of intravenous immunoglobulin （IVIG） is standard 
therapy for patients with acute KD. When administered 
sufficiently early in the disease course, this treatment 
promptly leads to defervescence and symptom 
remission in most patients. However, 10-15% of 
patients respond poorly, placing them at higher risk 
of developing coronary artery lesions （CALs）. By 
analyzing KD patients treated with a unified regimen 
and evaluating their response to this treatment using 
standardized criteria, we assessed the influence of the 
susceptibility SNPs of ITPKC and CASP3 on patients’ 
responsiveness to IVIG and risk of developing CAL. 
In this study, we found that KD patients possessing 
susceptibility alleles on both ITPKC and CASP3 had 
increased risk for IVIG resistance and CAL formation
［17］. This finding, together with previous knowledge 
of IP3 receptor, type 1［18］and NFATc2［19］cleavage 
in T cells by CASP3, highlighted the possibility that 
CASP3 also acts as a negative regulator of the Ca2+/
NFAT pathway in the pathophysiology of KD （Figure 
2）. Cyclosporine, a calcineurin inhibitor that suppresses 
this signal transduction pathway specifically, has drawn 
considerable attention as an effective drug for refractory 
KD patients［20,21］, and a phase III clinical trial of 
cyclosporine in KD patients predicted to show resistance 
to IVIG is currently underway at the initiative of Chiba 
University （http://www.chiba-crc.jp/kaica_trial-pc/
index.html）.
Ⅶ．Future direction
 Unfortunately, even when their genetic effects 
are considered together,  the currently known 
susceptibility genes for KD do not fully account for 
familial aggregation or different incidence ratios 
among ethnicities. It is likely that there are many more 
susceptibility genes unidentified as yet. It is also clear 
that higher statistical power than in previous studies 
is needed to identify common variants with minor 
effects that were missed in previous GWAS. However, 
increasing the sample size is easier said than done, 
especially for an acute illness where most patients are 
infants or children. Integration of multiple GWAS is a 
possible solution to this issue, which can increase the 
number of samples and consequently statistical power 
without requiring the collection of new samples or 
genotyping. We are now conducting a meta-analysis of 
three GWA studies with Korean and Taiwanese research 
groups who have published GWAS papers using their 
own samples. 
 Recently, the contribution of rare genetic variations 
and a greater number of individual mutations to the 
pathogenesis of common diseases has been increasingly 
recognized. Although the cost is still quite high at 
present, analyzing thousands of samples using next-
generation sequencers will become affordable in the 
near future. Clarifying more and more genetic factors 
relating to KD, including common, rare, and individual 
factors, will bring us closer to solving the mystery of 
this disease. 
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